Over decades, Ellen Sigal has emerged as a Washington insider in oncology, someone who has the ability to convene key players in academia, industry and government.
First, Congress should follow through on increasing the NIH budget by $2 billion in fiscal 2017, said Nancy Davidson, president of the American Association for Cancer Research.
Now, President Trump's budget proposal seeks to drop the NIH budget to $25.9 billion. That's $1.2 billion below the FY 2003 level, the year when the doubling was completed. These are absolute numbers. Adjusting for inflation will erode these funds even more.
Steve Hahn didn't apply for the job of Chief Operating Officer at MD Anderson Cancer Center. In fact, there was no COO job to apply to, and conversations that preceded the announcement of his new role took less than a week.
Marcia Crosse: This “failure of the adverse event reporting system” should serve as a “wake up call”
Hundreds of women were injured or have died from upstaging of unsuspected uterine cancer by power morcellation because FDA didn’t know the actual risk of cancer in fibroids, and hospitals failed to report harm, according to the U.S. Government Accountability Office.Between 1991 and 2014, FDA cleared 25 submissions for power morcellators to be marketed in the U.S. The GAO report notes that FDA had been aware of the device's potential for spreading tissue since 1991.
The data on the second most common blood cancer—with genomic information from about 1,400 patients—was compiled by the Multiple Myeloma Research Foundation through a genome mapping initiative and a $40 million network of clinical trials.
The wide-ranging public health initiative will cease to exist on Jan. 20—eight days short of a year after it was created—when the keys to the White House are handed over to Donald Trump.
In a 17-institution inspection sparked by reports of patient harm and death resulting from power morcellators and contaminated duodenoscopes, FDA found that nearly all hospitals surveyed either failed to report adverse events or didn't have proper reporting and documentation procedures in place.
In an in-depth interview with The Cancer Letter, an FDA official clarified the agency's criteria for approval of drugs that target PD-1 and PD-L1.
Nancy Davidson was named executive director of the Fred Hutchinson/University of Washington Cancer Consortium effective Dec. 1. For nearly eight years, Davidson has served as director of the University of Pittsburgh Cancer Institute.
